Procept
Executive Summary
Cambridge, Massachusetts-based immunologic drug R&D firm signs five-year collaborative R&D agreement with Bristol-Myers Squibb supporting Procept collaborative research with Ellis Reinherz at the Dana-Farber Cancer Institute. Bristol-Myers Squibb will have exclusive worldwide rights to therapeutic applications of the proprietary receptor technology to combat autoimmune disease and organ transplant rejection, and Procept has retained certain manufacturing and marketing rights to the products. In a separate transaction, Bristol made "a minority equity investment" in Procept.